| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Oct 20, 2020Study Reports 84% Back Pain Responder Rate and 69% Profound Responder Rate at 12 Months(1)Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced statistically significant 12-month results from a large, multicenter randomized controlled trial (RCT) that...
Oct 7, 2020A World's First That Combines Innovative Technologies: Titan nanoLOCK™ Surface Technology and NavigationMedtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. launch of Adaptix™ Interbody System, the first navigated titanium implant with Titan nanoLOCK™...
-
Oct 6, 2020ELITE is the Only Study of a Rechargeable Sacral Neurostimulation System to Include All Four Indications, Including Fecal Incontinence, Which Affects Millions
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first patient was implanted in its ELITE study of the InterStim™ Micro system — the only study of a...
-
Sep 25, 2020U.S. Patent and Trademark Office Rejects IPR Challenge to Medtronic Patent
Medtronic (NYSE:MDT) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim™ systems. The Patent Trial and Appeal...
-
Aug 20, 2020ELITE Study Designed to Confirm Long-Term Safety, Efficacy and Patient Benefit of Sacral Neuromodulation with the InterStim™ Micro System for Treatment of Overactive Bladder, Fecal Incontinence and Non-Obstructive Urinary Retention
DUBLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has begun recruitment of the prospective, multicenter, global,...